XENOMICS ANNOUNCES DEVELOPMENT OF TEST FOR THE GENETIC MARKER FOR ACUTE MYELOID LEUKEMIA (AML)

Xenomics, Inc., the source of next-generation medical DNA diagnostic tests, announced that it has developed a proprietary test for the detection of NPM gene mutations, a recently discovered genetic marker for Acute Myeloid Leukemia (AML). Xenomics already holds the exclusive license for the use of that marker. Yahoo News (http://biz.yahoo.com/prnews/060929/nyf016.html?.v=70)